Antibody directed enzyme prodrug therapy has the potential to be an effective therapy for most common solid cancers. Clinical studies with CPG2 system have shown the feasibility of this approach. The key limitation has been immunogenicity of the enzyme. Technologies now exist to eliminate this problem. Non-immunogenic enzymes in combination with prodrugs that generate potent cytotoxic drugs can provide a powerful approach to cancer therapy. ADEPT has the potential to be non -toxic to normal tissue and can therefore be combined with other modalities including immunotherapy for greater clinical benefit.

中文翻译：

---

抗体导向酶前药治疗（ADEPT）：试验和磨难

抗体导向的酶前药疗法有可能成为大多数常见实体癌的有效疗法。CPG2系统的临床研究表明了这种方法的可行性。关键限制是酶的免疫原性。现在存在消除该问题的技术。非免疫原性酶与产生强力细胞毒性药物的前药组合可以为癌症治疗提供有力的方法。ADEPT具有对正常组织无毒的潜力，因此可以与包括免疫疗法在内的其他方式结合使用，以取得更大的临床收益。